GlassScriptPhysician profile
Susan G Barner
NPI 1205804994
$4,482.37
in general payments reported to CMS, 2019-2025
19 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $923 · 2022: $187 · 2023: $723 · 2024: $1,182 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,359.90 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $591.92 | 2023-2025 | Azstarys |
| Abbvie INC. | $495.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $450.84 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $391.11 | 2021-2025 | Aplenzin |
| Alkermes, INC. | $373.56 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $363.12 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $293.32 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.73 | 2021-2025 | Caplyta |
| Neos Therapeutics, LP | $264.86 | 2025 | Adzenys Xr-Odt, Exxua |
| Vanda Pharmaceuticals INC. | $231.70 | 2024-2025 | Fanapt, Hetlioz |
| Harmony Biosciences LLC | $208.94 | 2023-2024 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $123.24 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $114.29 | 2021 | |
| Lundbeck LLC | $99.14 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $75.33 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $47.11 | 2021 | |
| Jazz Pharmaceuticals INC. | $37.55 | 2021 | |
| Tris Pharma INC | $32.98 | 2023-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $18.77 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Barner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.